DE69735870D1 - Verwendung von Aminosäuren zur Herstellung eines Arzneimittels zur Hemmung oder Aktivierung von Glutaminsäure im Gehirn - Google Patents

Verwendung von Aminosäuren zur Herstellung eines Arzneimittels zur Hemmung oder Aktivierung von Glutaminsäure im Gehirn

Info

Publication number
DE69735870D1
DE69735870D1 DE69735870T DE69735870T DE69735870D1 DE 69735870 D1 DE69735870 D1 DE 69735870D1 DE 69735870 T DE69735870 T DE 69735870T DE 69735870 T DE69735870 T DE 69735870T DE 69735870 D1 DE69735870 D1 DE 69735870D1
Authority
DE
Germany
Prior art keywords
medicament
brain
inhibiting
activating
manufacture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69735870T
Other languages
English (en)
Other versions
DE69735870T2 (de
Inventor
Kunio Torii
Takashi Kondo
Hrudananda Mallick
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ajinomoto Co Inc
Japan Science and Technology Agency
Original Assignee
Ajinomoto Co Inc
Japan Science and Technology Agency
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ajinomoto Co Inc, Japan Science and Technology Agency filed Critical Ajinomoto Co Inc
Publication of DE69735870D1 publication Critical patent/DE69735870D1/de
Application granted granted Critical
Publication of DE69735870T2 publication Critical patent/DE69735870T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE69735870T 1996-08-12 1997-08-12 Verwendung von Aminosäuren zur Herstellung eines Arzneimittels zur Hemmung oder Aktivierung von Glutaminsäure im Gehirn Expired - Fee Related DE69735870T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP8212838A JPH1053521A (ja) 1996-08-12 1996-08-12 脳内グルタミン酸の活性抑制剤および活性増強剤
JP21283896 1996-08-12

Publications (2)

Publication Number Publication Date
DE69735870D1 true DE69735870D1 (de) 2006-06-22
DE69735870T2 DE69735870T2 (de) 2006-11-30

Family

ID=16629192

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69735870T Expired - Fee Related DE69735870T2 (de) 1996-08-12 1997-08-12 Verwendung von Aminosäuren zur Herstellung eines Arzneimittels zur Hemmung oder Aktivierung von Glutaminsäure im Gehirn

Country Status (5)

Country Link
US (1) US5990167A (de)
EP (1) EP0827744B1 (de)
JP (1) JPH1053521A (de)
CA (1) CA2212904C (de)
DE (1) DE69735870T2 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2004026296A1 (ja) * 2002-09-18 2006-01-12 味の素株式会社 抗ストレス性疾患組成物
EP1908492A4 (de) * 2005-06-22 2008-12-10 Ajinomoto Kk Metabotroper glutamat-rezeptor-aktivator
CA2622204C (en) 2005-09-12 2016-10-11 Abela Pharmaceuticals, Inc. Systems for removing dimethyl sulfoxide (dmso) or related compounds, or odors associated with same
WO2007033180A1 (en) 2005-09-12 2007-03-22 Abela Pharmaceuticals, Inc. Materials for facilitating administration of dimethyl sulfoxide (dmso) and related compounds
WO2007033082A2 (en) 2005-09-12 2007-03-22 Abela Pharmaceuticals, Inc. Compositions comprising dimethyl sulfoxide (dmso)
US8480797B2 (en) 2005-09-12 2013-07-09 Abela Pharmaceuticals, Inc. Activated carbon systems for facilitating use of dimethyl sulfoxide (DMSO) by removal of same, related compounds, or associated odors
BRPI0921494A2 (pt) 2008-11-03 2018-10-30 Prad Reasearch And Development Ltd método de planejamento de uma operação de amostragem para uma formação subterrãnea, método de contolar uma operação de amostragem de formação subterrânea, método de controlar uma operação de perfuração para uma formação subterrãnea, e método de realizar uma amostragem durante a operação de perfuração.
JP5947721B2 (ja) 2009-10-30 2016-07-06 アベラ ファーマスーティカルズ インコーポレイテッド 変形性関節症を治療するためのジメチルスルホキシド（ｄｍｓｏ）およびメチルスルホニルメタン（ｍｓｍ）製剤
JP2012102054A (ja) * 2010-11-11 2012-05-31 Kyodo Milk Industry Co Ltd 腸内ポリアミン増強剤
DE102011056142A1 (de) * 2011-12-07 2013-06-13 Manfred Rüdinger Metabolisierbare Salze und deren Verwendung in Diagnostik und Therapie
JP2013184956A (ja) * 2012-03-09 2013-09-19 Kyodo Milk Industry Co Ltd 学習・記憶能力を増強するための食品
JP5881801B2 (ja) * 2014-10-29 2016-03-09 協同乳業株式会社 腸内ポリアミン増強剤
JOP20190146A1 (ar) 2016-12-19 2019-06-18 Axcella Health Inc تركيبات حمض أميني وطرق لمعالجة أمراض الكبد
CU20200012A7 (es) 2017-08-14 2021-02-04 Axcella Health Inc Composiciones de aminoácidos para el tratamiento de enfermedad hepática
JP2021527670A (ja) 2018-06-20 2021-10-14 アクセラ・ヘルス・インコーポレイテッドＡｘｃｅｌｌａ Ｈｅａｌｔｈ Ｉｎｃ． 筋肉中の脂肪浸潤の治療のための組成物及び方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4372774A (en) * 1978-08-17 1983-02-08 Pilkington Brothers Limited Thermal treatment of glass
JP2757960B2 (ja) * 1988-10-17 1998-05-25 サントリー株式会社 （２Ｒ，３Ｓ，４Ｓ）−α−（カルボキシシクロプロピル）グリシン
JP2814529B2 (ja) * 1989-03-16 1998-10-22 味の素株式会社 虚血性脳障害治療薬
JPH03261748A (ja) * 1990-03-09 1991-11-21 Suntory Ltd ３′―位置換ｌ―２（カルボキシシクロプロピル）グリシン類及びその製造法
JPH03275631A (ja) * 1990-03-19 1991-12-06 Ajinomoto Co Inc 抗痴呆薬
US5668117A (en) * 1991-02-22 1997-09-16 Shapiro; Howard K. Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments
DE69210214T2 (de) * 1991-10-18 1996-10-02 Suntory Ltd 2-(2,3-dicarboxycyclopropyl)-glycin und ein verfahren zu ihrer herstellung
WO1993013764A1 (en) * 1992-01-10 1993-07-22 Irina Alexeevna Komissarova Pharmaceutical preparation of antistress, stress-preventive and nootropic action
US5373085A (en) * 1992-09-28 1994-12-13 Fox; Sidney W. Memory enhancing thermal proteins
US5602150A (en) * 1992-10-02 1997-02-11 Research Foundation For Mental Hygiene, Inc. Treatment of central nervous system disorders associated with psychotic behavior and dementia with a combination of neuroleptic drugs and taurine, or derivatives thereof, to prevent the development of tardive dyskinesia
AU679020B2 (en) * 1992-12-23 1997-06-19 Abbott Laboratories Medical foods for the nutritional support of infant/toddler metabolic diseases
US5691325A (en) * 1994-01-14 1997-11-25 Sandyk; Reuven Method for ameliorating age-related disease conditions
US5470846A (en) * 1994-01-14 1995-11-28 Sandyk; Reuven Treatment of neurological and mental disorders
JPH07247253A (ja) * 1994-03-11 1995-09-26 Suntory Ltd （２ｓ）−２−（２−カルボキシ−５−メチレンシクロヘキシル）グリシン類

Also Published As

Publication number Publication date
US5990167A (en) 1999-11-23
CA2212904C (en) 2002-10-22
EP0827744A2 (de) 1998-03-11
JPH1053521A (ja) 1998-02-24
EP0827744B1 (de) 2006-05-17
CA2212904A1 (en) 1998-02-12
DE69735870T2 (de) 2006-11-30
EP0827744A3 (de) 2000-05-17

Similar Documents

Publication Publication Date Title
DE69316405T2 (de) Verfahren zur fermentativen Herstellung von Aminosäuren
DE69735870D1 (de) Verwendung von Aminosäuren zur Herstellung eines Arzneimittels zur Hemmung oder Aktivierung von Glutaminsäure im Gehirn
DE69635493D1 (de) Verfahren zur herstellung von l-aminosäuren
DE69403610T2 (de) Verfahren zur Herstellung von Ameisensäure und ihren Derivaten
DE69727260D1 (de) Verfahren zur Herstellung von L-Lysin
DE68919246T2 (de) Verfahren zur Herstellung von Aminosäuren.
DE69535643D1 (de) Verfahren zur fermentativen Herstellung von L-Lysin und L-glutaminsäure
DE69129899T2 (de) Verfahren zur Herstellung von D-Alpha-Aminosäuren
DE69514865D1 (de) Verfahren zur Herstellung von L-Asparaginsäure
DE69801383D1 (de) Verfahren zur Herstellung von N-langkettig acylsubstituierten sauren Aminosäuren oder deren Salzen
DE59500099D1 (de) Verfahren zur Herstellung von optisch aktiven Amino-alkoholen
DE59711908D1 (de) Verfahren zur Herstellung von Salzen von Säuregruppen tragenden pharmazeutischen Wirkstoffen
DE69528008T2 (de) Verfahren zur Herstellung von optisch-aktiven 4-Hydroxy-2-Ketoglutarsäuren
DE59405969D1 (de) Verfahren zur Herstellung von Polyasparaginsäure
DE59603846D1 (de) Verfahren zur Herstellung von aromatischen oder heteroaromatischen Nitrilen
DE69614733D1 (de) Verfahren zur Herstellung von optisch aktiver Aminosäure
DE69431097T2 (de) Verfahren zur Herstellung von humanem Serumalbumin
DE59604613D1 (de) Verfahren zur herstellung von optisch aktiven alpha-aminosäuren und alpha-aminosäure-derivaten
DE69300037T2 (de) Verwendung von Bucillamin zur Herstellung eines Arzneimittels zur Behandlung von Cystinuria.
DE69616085D1 (de) Aminonitril-zwischenprodukte zur herstellung von 2-hydroxyethyliminodiessigsäure
DE69510798D1 (de) Verfahren zur herstellung von kalziumsalzen von [s,s]-äthylendiamin- n,n'-dibernsteinsäure
DE69621276D1 (de) Verfahren zur Herstellung von Biphenylen- und Bisphenylenphosphiten
DE69805744T2 (de) Verfahren zur Herstellung von alpha-Aminonitrilen und alpha-Aminosäuren
DE69422953D1 (de) Verfahren zur Herstellung von D-Milchsäure und L-Lactamid
DE69803247T2 (de) Verfahren zur Herstellung von aliphatischen oder cyclaliphatischen Chloriden

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee